<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Washington</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>University of Washington</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Seattle, Washington, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1861</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.washington.edu/" target="_blank">https://www.washington.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Neuroimaging, Biomarkers</td>
</tr>
</table>
<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Washington</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>University of Washington</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Seattle, Washington, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1861</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.washington.edu/" target="_blank">https://www.washington.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Neuroimaging, Biomarkers</td>
</tr>
</table>
The University of Washington (UW) is a leading public research university located in Seattle, Washington. Founded in 1861, UW has grown to become one of the world's premier institutions for neuroscience and neurodegenerative disease research, with particular strength in Alzheimer's disease, Parkinson's disease, and ALS["@university"].
The university's research programs are housed within the UW School of Medicine and the UW College of Arts and Sciences, with major research centers including the Alzheimer's Disease Research Center and the Parkinson's Disease Research Center. UW researchers have made fundamental contributions to understanding protein aggregation, neuroinflammation, and the development of novel therapeutics["@uw"].
The University of Washington's involvement in neuroscience research has grown steadily since the mid-20th century:
UW hosts one of the nation's leading Alzheimer's disease research programs:
The Parkinson's program encompasses comprehensive research:
UW is a major center for ALS research:
One of 33 NIH-funded Alzheimer's Disease Research Centers, conducting comprehensive research from basic science to clinical care.
A state-of-the-art facility providing clinical care while conducting research on memory disorders and dementia.
Advanced neuroimaging facility supporting research on brain structure and function in neurodegenerative diseases.
| Researcher | H-index | Focus Areas |
|------------|---------|-------------|
| Dr. Thomas J. Grabowski | 85 | Alzheimer's Disease, Neuroimaging |
| Dr. James B. Leverenz | 110 | Parkinson's Disease, Lewy Body Dementia |
| Dr. Catherine L. Teng | 60 | Alzheimer's Disease, Clinical Trials |
| Dr. Michael J. Westerfield | 55 | Parkinson's Disease, Movement Disorders |
| Dr. Brittany N. Jutkowitz | 45 | ALS, Motor Neuron Disease |
UW actively participates in numerous clinical trials:
UW offers comprehensive training programs:
UW maintains extensive collaborations:
The Alzheimer's Disease Research Center (ADRC) at UW is one of 33 NIH-funded Alzheimer's Disease Research Centers nationwide. Established in the 1970s, the ADRC has been at the forefront of Alzheimer's disease research for over five decades[@uw]. The center operates under the leadership of Dr. Thomas J. Grabowski, whose research focuses on longitudinal amyloid and tau PET imaging in preclinical Alzheimer's disease[@grabowski2023].
The ADRC pursues several major research themes:
Biomarker Development: UW researchers have pioneered the development of blood-based biomarkers for early Alzheimer's disease detection. Recent work by Chow et al. (2024) demonstrated that plasma biomarker trajectories can identify individuals in the preclinical phase of Alzheimer's disease, potentially enabling interventions before significant neurodegeneration occurs[@chow2024]. The center has also contributed to understanding how APOE genotype affects amyloid and tau deposition differently across racial groups[@chen2024].
Neuroimaging: The Integrated Brain Imaging Center (IBIC) houses state-of-the-art PET and MRI facilities. UW researchers have developed novel PET tracers for detecting amyloid-beta plaques and tau neurofibrillary tangles. Dr. Grabowski's work on longitudinal amyloid and tau PET has provided critical insights into the temporal sequence of biomarker changes in preclinical AD[@grabowski2023].
Clinical Trials: The ADRC conducts extensive Phase 1-3 clinical trials testing novel therapeutic approaches including amyloid-targeting antibodies, tau-targeting agents, and neuroprotective compounds. The center participates in the Dominantly Inherited Alzheimer Network (DIAN), studying individuals with genetic forms of Alzheimer's disease[@bateman2022].
UW researchers have led major epidemiological studies on Alzheimer's disease risk factors. The research program examines how lifestyle factors, genetic predisposition, and environmental exposures interact to influence disease risk. Studies have particularly focused on understanding Alzheimer's disease in diverse populations, including research on neuroinflammation in African American populations[@li2023].
The Parkinson's Disease Research Center at UW, led by Dr. James B. Leverenz (H-index 110), represents one of the premier Parkinson's research programs in the United States. Dr. Leverenz's work has focused on the clinical features of Parkinson's disease with Lewy body pathology, providing critical insights into the relationship between alpha-synuclein pathology and clinical manifestations[@leverenz2022].
UW investigators conduct extensive research on the motor symptoms of Parkinson's disease:
Tremor and Bradykinesia: Studies examining the underlying mechanisms of tremor and bradykinesia, including work on basal ganglia circuitry and the effects of dopaminergic therapy.
Gait Dysfunction: Research on freezing of gait and postural instability, including development of novel assessment tools and intervention strategies.
Deep Brain Stimulation: UW has been a pioneer in deep brain stimulation (DBS) surgery for Parkinson's disease. Long-term outcomes studies have demonstrated the efficacy of DBS in improving motor function and quality of life[@hauser2023]. Researchers are investigating optimal stimulation parameters and target selection.
Recognizing that non-motor symptoms often have greater impact on quality of life, UW researchers investigate:
Cognitive Impairment: Studies on PD-associated dementia and mild cognitive impairment, including work on CSF biomarkers that predict cognitive decline[@kelley2024].
Depression and Anxiety: Research on mood disorders in Parkinson's disease and their treatment.
Sleep Disorders: Investigation of REM sleep behavior disorder and its relationship to disease progression.
Olfactory Dysfunction: Studies on smell loss as a prodromal marker.
Recent research has focused on developing biomarkers for Parkinson's disease diagnosis and progression tracking. Poston et al. (2023) used diffusion MRI to reveal microstructural changes in Parkinson's disease, providing new insights into disease pathophysiology[@poston2023]. Additionally, Song et al. (2024) demonstrated that neuroinflammation drives Parkinson's disease progression, identifying potential therapeutic targets[@song2024]. Jankovic et al. (2024) developed a Parkinson's disease subtyping approach based on CSF biomarkers[@jankovic2024].
Dr. Leverenz's research has particularly focused on Lewy body dementia, including work on synaptic loss and neurofibrillary tangle formation in this condition[@masliah2023]. Studies examine the relationship between Lewy body pathology and clinical features, including fluctuations in cognition, visual hallucinations, and parkinsonism.
The ALS research program at UW, led by Dr. Brittany N. Jutkowitz, encompasses comprehensive basic science and clinical research on amyotrophic lateral sclerosis. The program investigates genetic causes, disease mechanisms, and potential therapeutic approaches.
UW researchers have contributed to identifying novel genetic causes of ALS. Studies examine the role of established genes (C9orf72, SOD1, TARDBP, FUS) and search for new genetic contributors to the disease.
Protein Aggregation: Investigation of TDP-43 proteinopathy, the hallmark pathological finding in most ALS cases. Tennekoon et al. (2023) examined TDP-43 pathology in ALS and its correlation with clinical phenotype[@tennikov2023].
Excitotoxicity: Studies on glutamate-mediated excitotoxicity and its contribution to motor neuron death.
Neuroinflammation: Research on the role of glial cells and inflammatory pathways in disease progression.
UW participates in national ALS clinical trials testing novel therapeutic agents. The center operates a multidisciplinary ALS clinic providing comprehensive care while enabling clinical research.
Hu et al. (2023) identified novel CSF biomarkers for ALS progression, potentially enabling better disease monitoring and clinical trial endpoints[@hu2023]. Spencer et al. (2023) reviewed neurotoxic mechanisms in ALS, providing a framework for developing new therapies[@spencer2023].
UW researchers investigate atypical parkinsonian disorders including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). Dr. Stamelou has contributed to updating the diagnosis and treatment of PSP[@stamelou2022].
Research focuses on:
A major research theme across all neurodegenerative disease programs at UW is neuroinflammation. Ritzel et al. (2022) conducted foundational work on astrocyte senescence and inflammatory signaling in the aging brain[@ritzel2022]. This research has implications for multiple neurodegenerative conditions and identifies potential therapeutic targets.
Research areas include:
UW researchers also investigate traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE). Bethel et al. (2023) studied neuroimaging patterns in autopsy-confirmed CTE, advancing understanding of this condition in athletes and military veterans[@bethel2023].
UW researchers have made significant contributions to understanding tau pathology in Alzheimer's disease. Querfurth et al. (2023) demonstrated that amyloid-beta can induce tau-independent neurodegeneration in vivo, challenging the traditional view that tau pathology is downstream of amyloid[@querfurth2023]. Morris et al. (2023) contributed to developing new research criteria for staging Alzheimer disease[@morris2023].
The university has invested in precision medicine approaches for neurodegenerative diseases, integrating genetic, biomarker, and clinical data to develop individualized treatment strategies.
UW has prioritized research on neurodegenerative diseases in diverse populations, recognizing that most research has historically been conducted in European ancestry populations. Studies examine disease manifestations, risk factors, and treatment responses across different ancestry groups.
UW offers comprehensive graduate training in neuroscience:
UW offers postdoctoral research fellowships in all neurodegenerative disease areas, providing training in research design, methodology, and scientific writing.
The IBIC provides:
A state-of-the-art facility supporting clinical research including:
Comprehensive facilities for mouse and rat models of neurodegenerative diseases, including:
UW participates in multiple NIH-funded research networks:
Strategic partnerships with pharmaceutical companies enable:
UW maintains research relationships with institutions worldwide, facilitating:
Single-Cell Genomics: UW researchers are applying single-cell approaches to understand cellular heterogeneity in neurodegenerative diseases.
Gene Therapy: Development of AAV-based gene therapies for genetic forms of Alzheimer's and Parkinson's disease.
iPSC Models: Induced pluripotent stem cell-derived neurons and glia for disease modeling and drug screening.
Digital Health: Development of smartphone-based monitoring tools and wearable sensors.